Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: Results of an Italian/Swiss multicenter survey

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4289-4295

  Mancuso, Andrea ^a   Sacchetta, S ^a   Saletti, P C ^b   Tronconi, C ^c   Milesi, L ^d   Garassino, M ^e   Martelli, O ^f   Leone, A ^a   Zivi, A ^a   Cerbone, L ^a   Recine, F ^a   Sollami, R ^a   Labianca, R ^d   Cavalli, F ^b   Sternberg, C N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e Hospital IGEA   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

Author keywords

ERCC1; Pancreatic cell carcinoma; Prognostic and predictive factors; Second line treatment

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE EXPRESSION; HEALTH SURVEY; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; ITALY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; SWITZERLAND; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PYRIMIDINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALVAGE THERAPY; SURVIVAL RATE;

EID: 78650245775     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trials. Semin Oncol 29(Suppl 20): 9-16, 2002. (Pubitemid 36207367)
3. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ and Ajani JA: Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107: 676-685, 2006.
4. Tempera MA, Behrman S, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H and Willett C: Pancreatic adenocarcinoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 3: 598-626, 2005.
5. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, Adler M, Detken S, Dörken B and Riess H: Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 23: Abstract 4031, 2005.
6. Nakachi K, Furuse J, Ishii H, Suzuki E and Yoshino M: Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37: 114-120, 2007.
7. Therasse P, Eisenhauer EA and Buyse M: REClST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42: 1322-1330, 2006.
8. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ and Kim NK: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.
9. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C and de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516, 2005.
10. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E and Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 94: 902-910, 2002.
11. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S and Benson A III: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate-infusion [FDR]) versus gemcitabine+oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24: abstract LBA4004, 2006.
12. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schoenekaes H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A and Wilkowski R: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952, 2006.
13. Viret F, Ychou M, Lepille D, Mineur L, Navarro F, Topart D, Fonck M, Goineau J, Madroszyk-Flandin A and Chouaki N: Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. J Clin Oncol 22: abstract 4118, 2004.
14. Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 28: 82, 2008.
15. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Gorner M, Molle M, Hilbig A, Dorken B, Riess H and Oettle H: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26: abstract 4508, 2008.
16. Rosell R, Taron M, Alberola V, Massutti B and Felip E: Genetic testing for chemotherapy in nonsmall cell lung cancer. Lung Cancer 41: S97-S102, 2003. (Pubitemid 36819001)
17. Reardon JT, Vaisman A, Chaney SG and Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro cyclohexylamineplatinum (IV) (JM216) platinum intraStrand DNA adducts. Cancer Res 59: 3968-3971, 1999.
18. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F and Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2000.
19. Melton DW KA and Nunez F: Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 111: 395-404, 1998.
20. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
21. Lord RV, Brabender J, Gandara, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV and Rosell R: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291, 2002.
22. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B and Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
23. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
24. Metzger R, Schneider PM and Baldus SE: Quantitative ERCC1 RNA expression identifies non-response to cis-platinum based neoadjuvant radiochemo-therapy for esophageal cancer. J Clin Oncol 20: abstract 130a, 2001.
25. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemomerapy. N Engl J Med 355: 983-991, 2006.
26. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R and Baselga J: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18: 522-528, 2007.